Drug intelligence / Profile preview

JMEY-TB05

Development stage: Preclinical
Lead developer: Jianming Pharmaceutical Group

Overview

JMEY-TB05 is an investigational drug candidate being developed by Jianming Pharmaceutical Group for the treatment of asthma. As of the current pipeline information, the drug is in the preclinical stage of development, specifically categorized under CMC (Chemistry, Manufacturing, and Controls) and preclinical testing. Detailed information regarding its molecular target, mechanism of action, and modality has not been publicly disclosed by the developer, though it is part of the company's respiratory disease portfolio.

Beyond the preview

Go deeper on JMEY-TB05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMEY-TB05.

Explore the full profile